Commentary: Rapalink-1 Increased Infarct Size in Early Cerebral Ischemia–Reperfusion With Increased Blood–Brain Barrier Disruption

@NeuroscienceNew https://t.co/8ztQ63AaXg

‘ Rapamycin/rapalogues are already clinically approved to Prevent: Organ transplant rejection (Knight and Kahan, 2006), Cancers (Fagone et al., 2013), and Cardiovascular disease (Sousa et al., 2001). ‘ https://t.co/tFEGvmMKpM

@KristerKauppi https://t.co/OKBfOfJ9Yo

Commentary: Rapalink-1 Increased Infarct Size in Early Cerebral Ischemia–Reperfusion With Increased Blood–Brain Barrier Disruption "If we are to use rapamycin and Rapalink-1 to treat stroke, dosing is key..." https://t.co/QBYzWeW4vW